To develop a novel vaccine delivery system based on the Staphylococcus aureus-derived FLIPr protein, which targets Fcγ receptors on antigen-presenting cells, to enhance immune responses and simplify formulation processes.
Key Findings:
rF9R successfully bound peptides and antigens, forming stable complexes that enhanced antigen delivery.
In vivo studies showed that the rF9R/rE7m complex elicited robust CD8+ T-cell responses.
Interpretation:
The rF9R platform serves as an efficient carrier and immunostimulatory component, providing a versatile method for delivering peptide and subunit vaccines.
Limitations:
Conclusion:
rF9R represents a promising strategy for advancing cancer immunotherapy by improving the immunogenicity and therapeutic efficacy of cancer vaccines.
